Troponin levels as a guide to treatment of pulmonary embolism

Current Opinion in Pulmonary Medicine

Volumn 9, Issue 5, 2003, Pages 374-377

  Horlander, Kenneth Todd ^a,c   Leeper, Kenneth V ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c Medical Office Tower ^*  (United States)

Author keywords

Pulmonary embolism; Troponin I; Troponin T

Indexed keywords

FIBRINOLYTIC AGENT; TROPONIN; TROPONIN C; TROPONIN I; TROPONIN T;

DRUG USE; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; FIBRINOLYTIC THERAPY; HEART DILATATION; HEART HEMODYNAMICS; HEART RIGHT VENTRICLE FUNCTION; HUMAN; LUNG EMBOLISM; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PREDICTION; PROTEIN BLOOD LEVEL; REVIEW;

ACUTE DISEASE; HUMANS; PULMONARY EMBOLISM; RISK ASSESSMENT; TROPONIN;

EID: 0041737618     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200309000-00006     Document Type: Review

References (37)

1. Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000, 36:959-969.
2. Goldhaber SZ: Treatment of acute PE. In Atlas of Heart Disease, vol. 3. Edited by Braunwald E, Goldhaber SZ. Philadelphia: Current Medicine; 1995.
3. Carson JL, Kelley MA, Duff A, et al.: The clinical course of pulmonary embolism. N Engl J Med 1992, 326:1240-1245.
4. Research Committee of the British Thoracic Society: Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992, 340:873-876.
5. Alpert JS,Smith R, Carlson J et al.: Mortality in patients treated for pulmonary embolism. JAMA 1976, 236:1477-1480.
6. Cannon CP, Goldhaber SZ: Cardiovascular risk stratification of pulmonary embolism. Am J Cardiol 1996, 78;1149-1151.
7. Kasper W, Konstantinides S, Geibel A, et al.: Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997, 30:1165-1171.
8. Giannitsis E, Muller-Bardorff M, Kurowski V, et al.: Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000, 102:211-217. Fifty-six confirmed PE patients were enrolled prospectively in this study to evaluate the prognostic value of troponin T levels. This was one of the first studies to show that increased troponin T levels were associated independently with mortality as well as prolonged hypotension, shock, and need for subsequent resuscitation. This study lends credence to the presumption that cardiac troponin levels may be used to stratify PE patients by risk.
9. Morrow DA, Cannon CP, Rifai N, et al.: Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001, 286:2405-2412.
10. Konstantinides S, Geibel A, Olschewski M, et al.: Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002, 106:1263-1268. Troponins were evaluated in 106 confirmed PE patients. Troponin level correlated with echocardiographic RVD, mortality, recurrent PE, and hospital course. This study adds strength to the argument that troponins can be used for risk stratification of APE patients.
11. Hamm CW, Goldmann BU, Heeschen C, et al.: Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997, 337:1648-1653.
12. Adams JE III, Bodor GS, Davila-Roman VG, et al.: Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation 1993, 88:101-106.
13. Ishii J, Nomura M, Okuma T, et al.: Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. Clin Chim Acta 2001, 312:69-79.
14. Porter GA, Norton T, Bennett WB: Troponin T, a predictor of death in chronic haemodialysis patients. Eur Heart J 1998, 19:N34-N37.
15. Perna ER, Macin SM, Parras JI, et al.: Cardiac troponin T levels are associated with poor short- and long-term prognosis in patients with acute cardiogenic pulmonary edema. Am Heart J 2002, 143:814-820.
16. Cupo P, Hering SE. Cardiac troponin I release after severe envenoming by Tityus serrulatus. Toxicon 2002, 40:823-830.
17. Logeart D, Beyne P, Cusson C, et al.: Evidence of cardiac myolysis in severe nonischemic heart failure and the potential role of increased wall strain. Am Heart J 2001, 141:247-253.
18. Douketis JD, Crowther MA, Stanton EB, et al.: Elevated cardiac troponin levels in patients with submassive pulmonary embolism. Arch Intern Med 2002, 162:79-81.
19. Weinberi I, Cukierman T, Chajek-Shaul T. Troponin T elevation in lobar lung disease. Postgrad Med J 2002, 78:244-245.
20. Kennon S, Barakat K, Hitman GA, et al.: Angiotensin-converting enzyme inhibition is associated with reduced troponin release in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 2001, 38:724-728.
21. Williams GH, Dluly RG: Diseases of the adrenal cortex. In Harrison's Principles of Internal Medicine, edn 14. Edited by Fauci AS, Braunwald E, Isselbacher KJ, et al. New York: McGraw-Hill Health Profession Division; 1998:2035-2057.
22. Jolobe OMP. Troponin T elevation in lobar lung disease [letter]. Postgrad Med J 2002, 78:443.
23. Coma-Canella I, Gamallo C, Martinez Onsurbe P, et al.: Acute right-ventricular infarction secondary to a massive pulmonary embolism. Eur Heart J 1998, 9:534-540.
24. Muller-Bardorff M, Weidtmann B, Giannitsis E, et al.: Release kinetics of cardiac troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem 2002, 48:673-675.
25. Meyer T, Binder L, Hruska N, et al.: Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol 2000, 36:1632-1636. Troponin levels were evaluated in 36 PE patients in this randomized, double-blind study. The authors found that 39% of these confirmed PE patients had an elevation in troponin I and that these patients were more likely to have more segmental defects on ventilation-perfusion lung scanning as well as right ventricular dilation by echocardiography.
26. Janata K, Holzer M, Laggner AN, et al.: Cardiac troponin T in the severity assessment of patients with pulmonary embolism: cohort study. BMJ 2003, 326:312-313.
27. Wolfe MW, Lee RT, Feldstein ML, et al.: Prognostic significance of right ventricular hypokinesis and perfusion lung scan defects in pulmonary embolism. Am Heart J 1994, 127:1371-1375.
28. Dieter RS, Ernst E, Ende DJ, et al.: Diagnostic utility of cardiac troponin-I levels in patients with suspected pulmonary embolism. Angiology 2002, 53:583-585. Troponin I levels were evaluated in 91 patients suspected of having APE who also had VO scans. Elevated troponin I levels were not found to correlate with V/O scan results, nor were they deemed useful in the evaluation of suspected PE patients.
29. Grifoni S, Olivotto I, Cecchini P, et al.: Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000, 101:2817-2822. This study evaluated 209 patients with confirmed PE, finding that 31% had submassive PE. This subgroup had a high rate of subsequent shock (10%) and inhospital mortality (5%). Echocardiographic evidence of RVD in otherwise normotensive patients with APE was therefore shown to be a useful means to stratify these patients by risk. The authors concluded that these patients represent a group that may benefit from more aggressive therapies.
30. Pruszczyk P, Szulc M, Torbicki A: Troponin levels in acute pulmonary embolism. Chest 2002, 122:2264-2265.
31. Ribeiro A, Lindmarker P, Johnsson H, et al.: Pulmonary embolism: one-year follow-up with echocardiography Doppler and five year survival analysis. Circulation 1999, 99:1325-1330. This important study is the longest published follow-up of patients with PE evaluated for echocardiographic evidence of persistent pulmonary hypertension and survival. PE patients were found to be more likely to have persistent pulmonary hypertension if their initial pulmonary systolic pressures were more than 50 mmHg or if they were older than 70 years. Those who had persistent pulmonary hypertension and RVD at 6 weeks were also less likely to survive at 5 years' follow-up.
32. McIntyre KM, Sasahara AA: Determinant of right ventricular function and haemodynamics after pulmonary embolism. Chest 1975, 65:534-543.
33. Konstantinides S, Geibel A, Kasper W: Submassive and massive pulmonary embolism: a target for thrombolytic therapy? Thromb Haemost 1999, 82(suppl 1):104-108.
34. Nass N, McConnell MV, Goldhaber SZ, et al.: Recovery of regional right ventricular function after pulmonary embolism. Am J Cardiol 1999, 83:804-806.
35. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomized trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993, 341:507-511.
36. Konstantinides S, Geibel A, Heusef G, et al.: The management strategies and prognosis of pulmonary embolism-3 trial investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002, 347:1143-1150.
37. Konstantinides S, Geibel A, Olschewski M, et al.: Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 1997, 96:882-888.